{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:56:37Z","timestamp":1790848597337,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T01:04:42Z","timestamp":1692061482000},"page":"S20-S28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S","title":["Medication-induced hair loss: An update"],"prefix":"10.1016","volume":"89","author":[{"given":"Lina","family":"Alhanshali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buontempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.04.022_bib1","series-title":"Hair Loss and Restoration","author":"Shapiro","year":"2015"},{"issue":"32","key":"10.1016\/j.jaad.2023.04.022_bib2","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II trial of Brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10094","key":"10.1016\/j.jaad.2023.04.022_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14740338.2020.1718103","article-title":"Risk of adverse events in lymphoma patients treated with Brentuximab vedotin: a systematic review and meta-analysis","volume":"19","author":"Gao","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-\u03b1 antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases Series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/bjd.17533","article-title":"New therapies and old side-effects in mycosis fungoides treatment: Brentuximab vedotin-induced alopecia","volume":"180","author":"Pileri","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-233161","article-title":"Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma","volume":"13","author":"Nixon","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib9","first-page":"205","article-title":"Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?","volume":"48","author":"Konstantinou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2023.04.022_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jdcr.2018.05.022","article-title":"Nivolumab-induced alopecia areata: A reversible factor of good prognosis?","volume":"4","author":"Lakhmiri","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib11","doi-asserted-by":"crossref","first-page":"e15427","DOI":"10.1111\/dth.15427","article-title":"Diffuse alopecia areata induced by Brentuximab vedotin therapy for advanced stage mycosis fungoides","volume":"35","author":"Canal-Garcia","year":"2022","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.jaad.2023.04.022_bib12","article-title":"Adalimumab-related alopecia in a patient affected by psoriasis","volume":"23","author":"Mel\u00e9-Ninot","year":"2017","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib13","first-page":"596","article-title":"Alopecia universalis and onychodystrophy during treatment with adalimumab","volume":"33","author":"Youssef","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib14","doi-asserted-by":"crossref","first-page":"e14090","DOI":"10.1111\/dth.14090","article-title":"Alopecia universalis secondary to adalimumab treatment for psoriasis in a child","volume":"33","author":"S\u00e1nchez-Pujol","year":"2020","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/0378-6323.113097","article-title":"Alopecia areata in a patient receiving infliximab","volume":"79","author":"Ormaechea-P\u00e9rez","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2023.04.022_bib16","article-title":"Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: A case report","volume":"8","author":"Chin","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jaad.2023.04.022_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdcr.2021.09.003","article-title":"Denosumab-induced alopecia areata with lichenoid eruption","volume":"17","author":"Dourra","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jdcr.2016.06.003","article-title":"Alopecia areata after denosumab treatment for osteoporosis","volume":"2","author":"Lyakhovitsky","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2019.10.012","article-title":"Ixekizumab-induced alopecia areata","volume":"6","author":"Eldirany","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000499030","article-title":"Alopecia diffusa while using interleukin-17 inhibitors against psoriasis vulgaris","volume":"11","author":"Yajima","year":"2019","journal-title":"Case Rep Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib21","first-page":"E13","article-title":"Alopecia areata universalis complicating daclizumab therapy for uveitis","volume":"93","author":"Rosenstein","year":"2014","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib22","doi-asserted-by":"crossref","first-page":"e13071","DOI":"10.1111\/dth.13071","article-title":"New onset\u00a0alopecia areata during secukinumab therapy","volume":"32","author":"Yalici Armagan","year":"2019","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-016-0156-z","article-title":"Severe infliximab-induced alopecia and scalp psoriasis in a woman with Crohn\u2019s disease: dramatic improvement after drug discontinuation and treatment with adjuvant systemic and topical therapies","volume":"6","author":"Udkoff","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2023.04.022_bib24","article-title":"Lichen planopilaris induced by infliximab: A case report","volume":"8","author":"McPhie","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1684\/ejd.2018.3270","article-title":"Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn\u2019s disease","volume":"28","author":"Amschler","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib26","doi-asserted-by":"crossref","first-page":"e13033","DOI":"10.1111\/dth.13033","article-title":"Adalimumab-induced scalp psoriasis with severe alopecia","volume":"32","author":"\u00d6zkur","year":"2019","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib27","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1002\/ibd.22922","article-title":"Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn\u2019s disease","volume":"19","author":"Kawashima","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"21","key":"10.1016\/j.jaad.2023.04.022_bib28","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.jaad.2023.04.022_bib29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.28591","article-title":"A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma","volume":"120","author":"Li","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/idoj.IDOJ_325_18","article-title":"Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: A prospective observational study of 76 cases","volume":"10","author":"Saraswat","year":"2019","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jdcr.2015.06.013","article-title":"Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline","volume":"1","author":"Chen","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.jaad.2023.04.022_bib32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","article-title":"A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"36","author":"Pongpudpunth","year":"2009","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.jaad.2023.04.022_bib33","article-title":"Cetuximab-induced crusted pustular eruption with patchy alopecia","volume":"20","author":"Fischer","year":"2014","journal-title":"Dermatol Online J"},{"issue":"12","key":"10.1016\/j.jaad.2023.04.022_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.annder.2020.08.043","article-title":"[Erlotinib-induced scarring alopecia with a folliculitis decalvans-like presentation]","volume":"147","author":"Dervout","year":"2020","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2023.04.022_bib35","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.144.11.1524","article-title":"Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib","volume":"144","author":"Donovan","year":"2008","journal-title":"Arch Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2023.04.022_bib36","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","article-title":"A case of cicatricial alopecia associated with erlotinib","volume":"23","author":"Yang","year":"2011","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","article-title":"Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib","volume":"70","author":"Chang","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s13555-021-00588-8","article-title":"Key clinical adverse events in patients with advanced basal cell carcinoma treated with sonidegib or vismodegib: A post hoc analysis","volume":"11","author":"Gutzmer","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000508825","article-title":"Hair loss in patients treated with vismodegib: A single-center retrospective study","volume":"6","author":"Villani","year":"2020","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib40","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/jdv.15469","article-title":"Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience","volume":"33","author":"Scalvenzi","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjd.13619","article-title":"Hair loss and Hedgehog inhibitors: a class effect?","volume":"173","author":"Ferguson","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000510121","article-title":"Vismodegib-induced alopecia: Trichoscopic and confocal microscopy evaluation","volume":"6","author":"Cantelli","year":"2020","journal-title":"Skin Appendage Disord"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/1078155220930334","article-title":"A new treatment of alopecia induced by palbociclib: topical cetirizine","volume":"27","author":"Caro","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2023.04.022_bib44","article-title":"Single centre experience of cutaneous toxicity associated with braf and mek inhibitor treatment in children","volume":"102","author":"Loka","year":"2017","journal-title":"Arch Dis Child"},{"issue":"26","key":"10.1016\/j.jaad.2023.04.022_bib45","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ejhpharm-2020-002347","article-title":"The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis","volume":"28","author":"Peng","year":"2021","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib47","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2015.01.011","article-title":"RASopathic alopecia: hair changes associated with vemurafenib therapy","volume":"72","author":"Piraccini","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"10.1016\/j.jaad.2023.04.022_bib48","doi-asserted-by":"crossref","first-page":"e15731","DOI":"10.1097\/MD.0000000000015731","article-title":"Risk of dermatologic and mucosal adverse events associated with PD-1\/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials","volume":"98","author":"Yang","year":"2019","journal-title":"Med (Baltim)"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib49","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia\u00a0(areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5021\/ad.2021.33.3.284","article-title":"Nivolumab-induced alopecia areata: A case report and literature review","volume":"33","author":"Kim","year":"2021","journal-title":"Ann Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib51","first-page":"E25","article-title":"Remote-onset\u00a0alopecia areata attributed to ipilimumab","volume":"104","author":"Pearson","year":"2019","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cia2.12236","article-title":"Alopecia areata following pembrolizumab: A case report and literature review","volume":"5","author":"Hara","year":"2022","journal-title":"J Cutan Immunol Allergy"},{"issue":"10","key":"10.1016\/j.jaad.2023.04.022_bib53","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/ijd.15595","article-title":"Avelumab-induced lichen planopilaris, a novel association","volume":"60","author":"Dominguez-Santas","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2023.04.022_bib54","doi-asserted-by":"crossref","first-page":"adv00792","DOI":"10.2340\/actadv.v102.2311","article-title":"Scarring alopecia under immune checkpoint blockade: a report of three cases","volume":"102","author":"Braasch","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ijt.ijt_1_17","article-title":"Nilotinib-induced keratosis pilaris associated with alopecia areata and eyebrow thinning","volume":"9","author":"Tawil","year":"2017","journal-title":"Int J Trichology"},{"issue":"13","key":"10.1016\/j.jaad.2023.04.022_bib56","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000445288","article-title":"Alectinib-induced alopecia in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"9","author":"Koizumi","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamadermatol.2013.1375","article-title":"A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib","volume":"149","author":"Hansen","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2023.04.022_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1590\/abd1806-4841.20164724","article-title":"Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib","volume":"91","author":"Leit\u00e3o","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib60","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1590\/abd1806-4841.20153084","article-title":"Pi\u00f1eiro Maceira JM, Sodr\u00e9 CT. Alopecia secondary to Anti-tumor Necrosis Factor-alpha therapy","volume":"90","author":"Ribeiro","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","article-title":"Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-\u03b1 blocker agents: report of five cases and review of the literature","volume":"25","author":"Ferran","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2023.04.022_bib63","doi-asserted-by":"crossref","first-page":"ofz278","DOI":"10.1093\/ofid\/ofz278","article-title":"Alopecia after switch to tenofovir alafenamide in 6 African American women","volume":"6","author":"El Zein","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.jaad.2023.04.022_bib64","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/09564624221096299","article-title":"Doravirine\/tenofovir disoproxyl fumarate\/lamivudine-induced alopecia: A case report","volume":"33","author":"Cattaneo","year":"2022","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3947\/ic.2014.46.2.103","article-title":"Alopecia areata associated with abacavir therapy","volume":"46","author":"Kim","year":"2014","journal-title":"Infect Chemother"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1592\/phco.23.1.104.31918","article-title":"Recurring chemotherapy-associated alopecia areata: case report and literature review","volume":"23","author":"Motl","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0253-7176.175136","article-title":"Alopecia areata Monolocularis in clozapine-induced hypereosinophilia","volume":"38","author":"Jha","year":"2016","journal-title":"Indian J Psychol Med"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib69","first-page":"579","article-title":"Alopecia areata associated with haloperidol","volume":"48","author":"Kubota","year":"1994","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0163-8343(88)90083-7","article-title":"Alopecia areata during lithium therapy. A case report","volume":"10","author":"Silvestri","year":"1988","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib71","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1590\/abd1806-4841.20142944","article-title":"Alopecia universalis during treatment with leflunomide and adalimumab \u2013case report","volume":"89","author":"Lazzarini","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib72","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mjd.2001.109852","article-title":"Alopecia areata occurring in sisters after administration of rifampicin","volume":"44","author":"McMillen","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08820130902896824","article-title":"Alopecia areata universalis after phenobarbital-induced anti-convulsant hypersensitivity syndrome","volume":"38","author":"Huang","year":"2009","journal-title":"Immunol Investig"},{"issue":"10","key":"10.1016\/j.jaad.2023.04.022_bib74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0000000000012387","article-title":"Carbamazepine-induced acute alopecia areata","volume":"97","author":"Rathore","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib75","first-page":"200","article-title":"Three cases of alopecia areata induced by zotepine","volume":"15","author":"Kubota","year":"1993","journal-title":"Acta Neurol (Napoli)"},{"issue":"9","key":"10.1016\/j.jaad.2023.04.022_bib76","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2340\/00015555-2982","article-title":"Alopecia areata-like hair loss accompanying toxic epidermal necrolysis","volume":"98","author":"Mashima","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib77","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/1060028014524534","article-title":"Anidulafungin-induced alopecia","volume":"48","author":"Ruiz-Ramos","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib78","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ced.14381","article-title":"Drug-induced alopecia areata?","volume":"46","author":"Murad","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib79","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4103\/jfmpc.jfmpc_65_20","article-title":"Teneligliptin-induced hair loss: A case report","volume":"9","author":"Agrawal","year":"2020","journal-title":"J Fam Med Prim Care"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib80","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/15569527.2014.948684","article-title":"Acitretin-induced alopecia areata: a case report","volume":"34","author":"Ozlu","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib81","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/09546630902991484","article-title":"A case of imiquimod-induced alopecia","volume":"21","author":"Conde","year":"2010","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib85","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","article-title":"Telogen Effluvium \u2013a review of the science and current obstacles","volume":"101","author":"Chien Yin","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.det.2012.08.002","article-title":"Drugs and hair loss","volume":"31","author":"Patel","year":"2013","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2023.04.022_bib87","series-title":"Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy","first-page":"215","article-title":"Drug-induced alopecia","author":"Lesiak","year":"2015"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib88","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.det.2007.01.005","article-title":"Drug reactions affecting hair: diagnosis","volume":"25","author":"Tosti","year":"2007","journal-title":"Dermatol Clin"},{"issue":"8","key":"10.1016\/j.jaad.2023.04.022_bib89","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.142.8.1000","article-title":"Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis","volume":"142","author":"Pearce","year":"2006","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib90","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.04.022_bib91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jdin.2022.01.002","article-title":"Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg\/kg\/d versus \u22650.5-mg\/kg\/d dosing in acne patients: A systematic review","volume":"6","author":"Lytvyn","year":"2022","journal-title":"JAAD Int"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib92","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1345\/aph.18346","article-title":"Alopecia due to psychotropic medications","volume":"33","author":"Gautam","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4103\/0253-7613.169587","article-title":"Dose-dependent valproate-induced alopecia in patients with mental disorders","volume":"47","author":"Tomita","year":"2015","journal-title":"Indian J Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib94","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1684\/epd.2014.0704","article-title":"The clinical pharmacology of traditional antiepileptic drugs","volume":"16","author":"Vajda","year":"2014","journal-title":"Epileptic Disord"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib95","doi-asserted-by":"crossref","first-page":"354","DOI":"10.7326\/0003-4819-123-5-199509010-00006","article-title":"Alopecia associated with fluconazole therapy","volume":"123","author":"Pappas","year":"1995","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jaad.2023.04.022_bib96","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/QAD.0b013e3281532b42","article-title":"Alopecia associated with ritonavir-boosted atazanavir therapy","volume":"21","author":"Torres","year":"2007","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10401230009147085","article-title":"Hair loss in psychopharmacology","volume":"12","author":"Mercke","year":"2000","journal-title":"Ann Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","article-title":"Drug-induced hair loss and hair growth. Incidence, management and avoidance","volume":"10","author":"Tosi","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2023.04.022_bib99","unstructured":"Saleh D, Nassereddin A, Cook C. Anagen effluvium. StatPearls Publishing. 2022"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.022_bib100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000485749","article-title":"Alopecia and associated toxic agents: A systematic review","volume":"4","author":"Yu","year":"2018","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.022_bib101","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaad.2022.03.009","article-title":"Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia","volume":"88","author":"Yin","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.022_bib102","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair disorders\u00a0in patients with cancer","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.022_bib103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(white star)","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib104","doi-asserted-by":"crossref","first-page":"e2020074","DOI":"10.5826\/dpc.1003a74","article-title":"Prevention and treatment of chemotherapy-induced alopecia","volume":"10","author":"Rossi","year":"2020","journal-title":"Dermatol Pract Concept"},{"issue":"8","key":"10.1016\/j.jaad.2023.04.022_bib105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archderm.140.8.1012-a","article-title":"Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles","volume":"140","author":"Ettefagh","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.022_bib106","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.022_bib107","doi-asserted-by":"crossref","first-page":"e14171","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: a review","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"issue":"20","key":"10.1016\/j.jaad.2023.04.022_bib108","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1200\/JCO.2012.46.9346","article-title":"Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib","volume":"31","author":"Shih","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2023.04.022_bib109","article-title":"Onset of frontal fibrosing alopecia during inhibition of Th1\/17 Pathways with ustekinumab","volume":"25","author":"King","year":"2019","journal-title":"Dermatol Online J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223007193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223007193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:09Z","timestamp":1759274889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223007193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0190962223007193"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.022","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-induced hair loss: An update","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}